<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62247">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02127736</url>
  </required_header>
  <id_info>
    <org_study_id>PSG40</org_study_id>
    <nct_id>NCT02127736</nct_id>
  </id_info>
  <brief_title>Pharmacological Conditioning of Sleep Patterns in Healthy Participants Using Amitriptylin</brief_title>
  <official_title>Pharmacological Conditioning of Sleep Patterns in Healthy Participants Using Amitriptylin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Winfried Rief</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philipps University Marburg Medical Center</source>
  <oversight_info>
    <authority>Germany: Philipps University Marburg</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether an Amitriptylin induced change in sleep
      patterns can be conditioned according to learning theory in healthy participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>N/A</study_design>
  <primary_outcome>
    <measure>Objective Total Sleep Time</measure>
    <time_frame>5 nights during the study</time_frame>
    <safety_issue>No</safety_issue>
    <description>assessed by polysomnography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of rapid eye movement (REM) sleep</measure>
    <time_frame>5 nights during the study</time_frame>
    <safety_issue>No</safety_issue>
    <description>assessed by polysomnography</description>
  </primary_outcome>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amitriptyline</intervention_name>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 18 years to 69 years

          -  willingness to refrain from alcohol consumption throughout the study

          -  regular sleeping habits

          -  fluent in German language

          -  is not dependent on driving to get to the study center

          -  provide written informed consent

          -  ability to understand the explanations and instructions given by the study physician
             and the investigator

        Exclusion Criteria:

          -  Contraindications to study medication intake according to the information sheet for
             health professionals (Summary of medicinal Product Characteristics, SmPC) assessed by
             physical examination (including ECG) and medical history

               -  allergies to amitriptyline hydrochloride or any of its ingredients

               -  acute intoxication with alcohol, analgetics, hypnotics or any other psychotropic
                  drug

               -  urinary retention

               -  delirium

               -  untreated closed-angle glaucoma

               -  prostatic hyperplasia

               -  pyloric stenosis

               -  paralytic ileus

               -  suicidal thoughts

               -  liver/ kidney/ pulmonary insufficiency

               -  myasthenia gravis

               -  hypokalemia

               -  bradycardia

               -  coronary heart disease, cardiac arrhythmias, long QT syndrome or other
                  clinically relevant cardiac disorders

               -  increased risk of seizures/ history of seizures

               -  substance dependence syndrome/ history of substance dependence syndrome

          -  Allergies to ingredients of placebo or novel-tasting drink (CS)

          -  currently pregnant (verified by urine pregnancy test) or lactating

          -  patients suffering from a mental disorder as verified by the International Diagnosis
             Checklists (IDCL)

          -  patients suffering from a medical condition (assessed by the study physician)

          -  Concomitant medication interfering with study medication intake due to potential
             interactions

          -  participation in any other clinical trial 3 months prior to visit 1

          -  employee of the Sponsor or the principal investigator
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Winfried Rief, Prof. Dr.</last_name>
    <phone>+49-6421-28 23657</phone>
    <email>rief@staff.uni-marburg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Psychology, Philipps University Marburg</name>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <zip>35032</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Winfried Rief, Prof. Dr.</last_name>
      <phone>+49-6421-28 23657</phone>
      <email>rief@staff.uni-marburg.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 16, 2014</lastchanged_date>
  <firstreceived_date>April 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Philipps University Marburg Medical Center</investigator_affiliation>
    <investigator_full_name>Winfried Rief</investigator_full_name>
    <investigator_title>Prof. Dr. Winfried Rief</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amitriptyline</mesh_term>
    <mesh_term>Amitriptyline, perphenazine drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
